Business
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
TORONTO, February 12, 2026--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for Duchenne muscular dystrophy ("Duchenne" or "DMD").
About this update from Satellos Bioscience Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1301,"height":302,"url":"https://media.zenfs.com/en/business-wire.com/81c6e458ea4da659b468baa31a410536"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/82VVvPsv1H76AI.uUExPeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyMztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/81c6e458ea4da659b468baa31a410536","width":960,"height":223},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/0oPTa6q7onTto9i9Udqg0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/81c6e458ea4da659b468baa31a410536","width":1200,"height":279}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"BASECAMP, a three-month, randomized, double-blind, placebo-controlled study, will evaluate SAT-3247’s safety and tolerability, and effect on muscle force, muscle quality and muscle regeneration","length":193,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":193,"olType":false},{"type":"text","content":"TORONTO, February 12, 2026--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for Duchenne muscular dystrophy ("Duchenne" or "DMD").","length":521,"tagName":"p"},{"type":"text","content":"The study will evaluate SAT-3247 in 51 ambulatory children with DMD aged 7, 8 or 9 years of age. Primary endpoints include safety, tolerability and effect on muscle force. Secondary endpoints will assess SAT-3247’s impact on muscle quality, function and regeneration.","length":267,"tagName":"p"},{"type":"text","content":""Designed as a potential pivotal trial, BASECAMP marks a significant step for Satellos in evaluating the therapeutic potential of SAT-3247 in children living with Duchenne," said Satellos Co-founder and CEO Frank Gleeson. "Data generated from BASECAMP could play a meaningful role in accelerating the development of SAT-3247 as a novel treatment for ...